InvestorsHub Logo
Followers 105
Posts 20514
Boards Moderated 0
Alias Born 06/30/2012

Re: None

Tuesday, 12/06/2016 6:54:34 PM

Tuesday, December 06, 2016 6:54:34 PM

Post# of 20617
One last thought tonight...

Dr Damaj would have never agreed to hand over another 12% of the total number of shares outstanding if FDA approval wasn't in the bag. He would be opening doors to a class action lawsuit by the shareholders. It would be a career ending misstep and one that would cost him dearly financially since he owns over 23M shares of the company. The deal was signed/done and HE chose to fulfill his obligation early "in the best interest of shareholders".

How much you want to bet that he is dotting the I's and crossing the T's on his Fluticare distribution plans? Watch how fast this comes online and in stores after approval. If Novalere can't dump until Q2 at the earliest, then why should we be overly concerned ?

Xyralid next, probably another overseas deal or two, then earnings / FDA approval within days of each other IMO. He/we have about 2 months in my view or we miss the all important allergy season sales. With the short interest declining, this is setting up for another run into next earnings release. Again if I am off base or illogical - do tell ?

Wouldn't surprise me if he has something else up his sleeve to add value as well. Guy is SMART and he delivers
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.